

## Press Release

### Change of Directors

**TOKYO, April 27, 2021** - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below. This change is subject to approval at the 16th Term Annual Shareholders Meeting and a decision at the Board of Directors meeting, both scheduled on June 18, 2021.

#### 1. Candidates for Directors (excluding Directors who are Audit & Supervisory Committee Members)

Name		Current Position
Yoshihiko Hatanaka	Reelection	Representative Director, Chairman of the Board
Kenji Yasukawa	Reelection	Representative Director, President and CEO
Naoki Okamura	Reelection	Representative Director, Executive Vice President, Chief Strategy Officer (CStO) and Chief Financial Officer (CFO)
Mamoru Sekiyama	Outside Reelection	Outside Director and Audit & Supervisory Committee Member, A.D. Works Group Co., Ltd.
Hiroshi Kawabe	Outside Reelection	Professor Emeritus, Keio University President, Foundation for Promotion of Medical Training
Tatsuro Ishizuka	Outside Reelection	Advisor, Hitachi, Ltd. President, The Hitachi Global Foundation Outside Director, K&O Energy Group Inc.
Takashi Tanaka	Outside New Candidate	Representative Director, Chairman of the Board, KDDI Director, Okinawa Cellular Telephone Company

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.

## 2. Candidate for Director who is an Audit & Supervisory Committee Member

Name		Current Position
Haruko Shibumura	Outside Reelection	Partner Lawyer, Homma & Partners Outside Director, TAMURA Corporation Outside Director, NICHIREKI CO., LTD.

The current position of the candidate for outside Director describes significant concurrent positions at other organizations pursuant to the Companies Act.

## 3. Directors to be retired

Outside Director

Keiko Yamagami

## 4. The Board of Directors as from June 18, 2021 (planned)

Yoshihiko Hatanaka (Representative Director, Chairman of the Board)

Kenji Yasukawa (Representative Director, President and CEO)

Naoki Okamura (Representative Director, Executive Vice President)

Mamoru Sekiyama (Outside Director)

Hiroshi Kawabe (Outside Director)

Tatsuro Ishizuka (Outside Director)

Takashi Tanaka (Outside Director)

Toru Yoshimitsu (Director, Audit & Supervisory Committee Member)

Hiroo Sasaki (Outside Director, Audit & Supervisory Committee Member)

Haruko Shibumura (Outside Director, Audit & Supervisory Committee Member)

Raita Takahashi (Outside Director, Audit & Supervisory Committee Member)

**About Astellas**

Astellas Pharma Inc., is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <https://www.astellas.com/en>.

**Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

---

**Contacts for inquiries or additional information:**

Astellas Pharma Inc.  
Corporate Advocacy & Relations  
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473